ClinicalTrials.gg
CompletedNCT02387814Updated Mar 5, 2019Results posted

A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment

A Phase 1 interventional study of Abemaciclib in Hepatic Insufficiency, sponsored by Eli Lilly and Company. Completed at 5 sites in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-05.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Hepatic Insufficiency by Eli Lilly and Company — 2 open to participants now, 2 under way, none of them phase 3. Hepatic Insufficiency · Eli Lilly and Company.

Enrollment
5th of 12
35 · median 34
Started
2015
the only one that year
Phase 1
12 of 12
2 open now
Registered
4th of 12
by date

Among the 12 studies in Hepatic Insufficiency by Eli Lilly and Company, this one is the 5th largest by enrollment, is the only one that started in 2015, is one of 12 in phase 1, and was the 4th registered.

Hepatic Insufficiency

113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.

Browse Hepatic Insufficiency studies →

Open to participants now

2 of the 12 studies in Hepatic Insufficiency by Eli Lilly and Company are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hepatic Insufficiency by Eli Lilly and Company, or all of them as a file.
02

Study summary

The study involves a single dose of a study drug called abemaciclib taken by mouth. The purpose of this study will be to measure how much study drug gets into the blood stream and how long the body takes to get rid of it when given to participants with mild, moderate, or severe liver impairment compared to healthy participants. In addition, the tolerability of the study drug will be evaluated.

This study will last approximately 3 weeks for each participant, including check-in and follow-up.

03

Conditions studied

  • Hepatic Insufficiency

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participants must be of non-
  • Have a of 18 to 40 kilograms per square meter (kg/m²)

Exclusion criteria

Exclusion Criteria:

  • No history of cardiovascular, renal, respiratory, gastrointestinal, endocrine or hematological disorders
  • Have known allergies to abemaciclib, related compounds, or any components of the formulation
  • No (HIV) infection or antibodies
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Abemaciclib: Normal Hepatic Function

    Single dose of Abemaciclib administered orally on Day 1 to participants with normal hepatic function.

    Drug: Abemaciclib

  • Experimental
    Abemaciclib: Mild Hepatic Impairment

    Single dose of Abemaciclib administered orally on Day 1 to participants with mild hepatic impairment.

    Drug: Abemaciclib

  • Experimental
    Abemaciclib: Moderate Hepatic Impairment

    Single dose of Abemaciclib administered orally on Day 1 to participants with moderate hepatic impairment.

    Drug: Abemaciclib

  • Experimental
    Abemaciclib: Severe Hepatic Impairment

    Single dose of Abemaciclib administered orally on Day 1 to participants with severe hepatic impairment.

    Drug: Abemaciclib

Interventions

  • Administered Orally

    Also known as: LY2835219

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Abemaciclib and Active Metabolites

    Time frame: Day 1: Predose, 1, 2, 3, 4, 6, 8, 10, 24, 48, 72, 96, 120, 144, 168, and 192 Hours Postdose

  2. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity(AUC[0-inf]) of Abemaciclib and Active Metabolites

    Time frame: Day 1: Predose, 1, 2, 3, 4, 6, 8, 10, 24, 48, 72, 96, 120, 144, 168, and 192 Hours Postdose

07

Results

Posted Jan 22, 2019

Participant flow

Participant flow — Overall Study
MilestoneAbemaciclib: Normal Hepatic FunctionAbemaciclib: Mild Hepatic ImpairmentAbemaciclib: Moderate Hepatic ImpairmentAbemaciclib: Severe Hepatic Impairment
Started109106
Received abemaciclib109106
Completed109106
Not completed0000

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Abemaciclib and Active Metabolites
Time frame:
Day 1: Predose, 1, 2, 3, 4, 6, 8, 10, 24, 48, 72, 96, 120, 144, 168, and 192 Hours Postdose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Abemaciclib and Active Metabolites
nanograms per milliliter (ng/mL)Abemaciclib: Normal Hepatic FunctionAbemaciclib: Mild Hepatic ImpairmentAbemaciclib: Moderate Hepatic ImpairmentAbemaciclib: Severe Hepatic Impairment
Abemaciclib133 ± 63109 ± 6583.9 ± 47156 ± 44
LSN283956731.2 ± 5726.0 ± 3113.6 ± 7117.4 ± 45
LSN310672910.4 ± 476.24 ± 274.96 ± 902.70 ± 41
LSN310672655.3 ± 4037.7 ± 3519.2 ± 7114.0 ± 27
PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity(AUC[0-inf]) of Abemaciclib and Active Metabolites
Time frame:
Day 1: Predose, 1, 2, 3, 4, 6, 8, 10, 24, 48, 72, 96, 120, 144, 168, and 192 Hours Postdose
Reported as:
Geometric mean · nanograms*hours/milliliter (ng*h/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity(AUC[0-inf]) of Abemaciclib and Active Metabolites
nanograms*hours/milliliter (ng*h/mL)Abemaciclib: Normal Hepatic FunctionAbemaciclib: Mild Hepatic ImpairmentAbemaciclib: Moderate Hepatic ImpairmentAbemaciclib: Severe Hepatic Impairment
Abemaciclib4460 ± 614280 ± 584940 ± 519310 ± 49
LSN28395671420 ± 401090 ± 34921 ± 46846 ± 33
LSN3106729480 ± 55257 ± 42211 ± 25135.3 ± NA
LSN31067263120 ± 402200 ± 391570 ± 571170 ± 30

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abemaciclib: Normal Hepatic Function—0/10 (0%)4/10 (40%)
Abemaciclib: Mild Hepatic Impairment—0/9 (0%)6/9 (66.7%)
Abemaciclib: Moderate Hepatic Impairment—1/10 (10%)7/10 (70%)
Abemaciclib: Severe Hepatic Impairment—0/6 (0%)3/6 (50%)
Most frequent serious events
Most frequent serious events
EventAbemaciclib: Normal Hepatic FunctionAbemaciclib: Mild Hepatic ImpairmentAbemaciclib: Moderate Hepatic ImpairmentAbemaciclib: Severe Hepatic Impairment
PneumoniaInfections and infestations0/100/91/100/6
Most frequent other events
Showing 10 of 20
Most frequent other events
EventAbemaciclib: Normal Hepatic FunctionAbemaciclib: Mild Hepatic ImpairmentAbemaciclib: Moderate Hepatic ImpairmentAbemaciclib: Severe Hepatic Impairment
HeadacheNervous system disorders3/102/91/100/6
Catheter site erythemaGeneral disorders0/102/90/100/6
DysgeusiaNervous system disorders0/102/90/100/6
EpistaxisRespiratory, thoracic and mediastinal disorders0/102/90/100/6
FatigueGeneral disorders0/100/92/100/6
NauseaGastrointestinal disorders0/100/91/101/6
Salivary hypersecretionGastrointestinal disorders0/100/90/101/6
Catheter site painGeneral disorders0/101/90/101/6
LacerationInjury, poisoning and procedural complications0/100/90/101/6
Abdominal distensionGastrointestinal disorders0/101/90/100/6

Baseline characteristics

All participants who received abemaciclib.

Age, Continuous
Age, Continuous(years)Abemaciclib: Normal Hepatic FunctionAbemaciclib: Mild Hepatic ImpairmentAbemaciclib: Moderate Hepatic ImpairmentAbemaciclib: Severe Hepatic ImpairmentTotal
Mean55.0 ± 4.856.6 ± 4.458.8 ± 5.553.2 ± 6.256.2 ± 5.3
Sex: Female, Male
Sex: Female, Male(Participants)Abemaciclib: Normal Hepatic FunctionAbemaciclib: Mild Hepatic ImpairmentAbemaciclib: Moderate Hepatic ImpairmentAbemaciclib: Severe Hepatic ImpairmentTotal
Female533213
Male567422
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Abemaciclib: Normal Hepatic FunctionAbemaciclib: Mild Hepatic ImpairmentAbemaciclib: Moderate Hepatic ImpairmentAbemaciclib: Severe Hepatic ImpairmentTotal
Hispanic or Latino22048
Not Hispanic or Latino8710227
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Abemaciclib: Normal Hepatic FunctionAbemaciclib: Mild Hepatic ImpairmentAbemaciclib: Moderate Hepatic ImpairmentAbemaciclib: Severe Hepatic ImpairmentTotal
American Indian or Alaska Native00011
Asian01001
Native Hawaiian or Other Pacific Islander00000
Black or African American31307
White777425
More than one race00000
Unknown or Not Reported00011
Region of Enrollment
Region of Enrollment(Participants)Abemaciclib: Normal Hepatic FunctionAbemaciclib: Mild Hepatic ImpairmentAbemaciclib: Moderate Hepatic ImpairmentAbemaciclib: Severe Hepatic ImpairmentTotal
United States10910635
08

Study locations

5 sites
  • DaVita Clinical Research
    Lakewood, Colorado 80228, United States
  • Clinical Pharmacology of Miami (CPMI)
    Miami, Florida 33014, United States
  • Orlando Clinical Research Center (OCRC)
    Orlando, Florida 32809, United States
  • Indiana University - Digestive and Liver Diseases
    Indianapolis, Indiana 46202, United States
  • DaVita Clinical Research
    Minneapolis, Minnesota 55404, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2015, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2019, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2015
First posted
Mar 13, 2015
Start
Mar 2015
Primary completionActual
Aug 2015
CompletionActual
Aug 2015
Results first posted
Jan 22, 2019
Last update
Mar 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02387814
Responsible party
Sponsor
First posted
Mar 13, 2015
Start date
Mar 2015
Primary completion
Aug 2015
Completion
Aug 2015
Results posted
Jan 22, 2019
Last update
Mar 5, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion